

## **Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference**

**TURKU, Finland / BOSTON, Massachusetts – September 6, 2023** – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that Dr Markku Jalkanen, PhD, CEO will present at the H.C. Wainwright Annual Global Investment Conference in New York City on September 12, 2023. In addition to the presentation, company management will be available for one-on-one meetings with investors.

### **H.C. Wainwright Global Investment Conference**

Date: Tuesday, September 12, 2023

Time: 10:30 a.m. ET

Location: Room Holmes I, 4<sup>th</sup> floor

Format: Company Presentation

**For more information please contact:**

#### **Investor Contact**

##### **LifeSci Advisors**

Daniel Ferry

Managing Director

[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)

+1 (617) 430-7576

#### **Media Contact**

##### **Faron Pharmaceuticals**

Jennifer C. Smith-Parker

Head of Communications

[Jennifer.Smith-Parker@faron.com](mailto:Jennifer.Smith-Parker@faron.com)

#### **About Faron Pharmaceuticals Ltd.**

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is *bexmarilimab*, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. *Bexmarilimab* is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at [www.faron.com](http://www.faron.com).